Published in Atherosclerosis on June 01, 1995
Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Invest (1998) 3.34
Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor. Biochem J (1999) 1.92
Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. J Clin Invest (1997) 1.71
Proteomic diversity of high density lipoproteins: our emerging understanding of its importance in lipid transport and beyond. J Lipid Res (2013) 1.57
The retinal pigment epithelium: something more than a constituent of the blood-retinal barrier--implications for the pathogenesis of diabetic retinopathy. J Biomed Biotechnol (2010) 1.52
Association between the severity of angiographic coronary artery disease and paraoxonase gene polymorphisms in the National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation (WISE) study. Am J Hum Genet (2002) 1.10
Increased selective uptake in vivo and in vitro of oxidized cholesteryl esters from high-density lipoprotein by rat liver parenchymal cells. Biochem J (1996) 0.89
Astaxanthin prevents changes in the activities of thioredoxin reductase and paraoxonase in hypercholesterolemic rabbits. J Clin Biochem Nutr (2012) 0.86
Human paraoxonase-1 (PON1): Gene structure and expression, promiscuous activities and multiple physiological roles. Gene (2015) 0.83
Probucol alleviates atherosclerosis and improves high density lipoprotein function. Lipids Health Dis (2011) 0.83
Subjects with low plasma HDL cholesterol levels are characterized by an inflammatory and oxidative phenotype. PLoS One (2013) 0.83
The assessment of carotid intima media thickness and serum paraoxonase-1 activity in Helicobacter pylori positive subjects. Lipids Health Dis (2010) 0.83
Paraoxonase: Its antiatherogenic role in chronic renal failure. Indian J Nephrol (2010) 0.80
Ciprofibrate increases paraoxonase activity in patients with metabolic syndrome. Br J Clin Pharmacol (2006) 0.80
HDL enhances oxidation of LDL in vitro in both men and women. Lipids Health Dis (2005) 0.79
Plasma apolipoprotein O level increased in the patients with acute coronary syndrome. J Lipid Res (2012) 0.79
Association between p.Leu54Met polymorphism at the paraoxonase-1 gene and plantar fascia thickness in young subjects with type 1 diabetes. Diabetes Care (2008) 0.79
Frequency distribution of the single-nucleotide -108C/T polymorphism at the promoter region of the PON1 gene in Asian Indians and its relationship with coronary artery disease. J Community Genet (2011) 0.78
Potential role of the interaction between equine estrogens, low-density lipoprotein (LDL) and high-density lipoprotein (HDL) in the prevention of coronary heart and neurodegenerative diseases in postmenopausal women. Lipids Health Dis (2003) 0.78
Systems biology approaches to understand the effects of nutrition and promote health. Br J Clin Pharmacol (2016) 0.78
Paraoxonase1, its Q192R polymorphism and HDL-cholesterol in relation to intensive cardiac care unit stay in ischemic heart disease. Indian J Hum Genet (2014) 0.76
Intravenous lipids for preterm infants: a review. Clin Med Insights Pediatr (2015) 0.76
Serum paraoxonase levels in patients with acute liver disease. Indian J Clin Biochem (2011) 0.76
The prevention and treatment effects of egg yolk high density lipoprotein on the formation of atherosclerosis plaque in rabbits. Iran J Basic Med Sci (2015) 0.75
Serum Paraoxonase Levels are Correlated with Impaired Aortic Functions in Patients with Chronic Kidney Disease. Zhonghua Minguo Xin Zang Xue Hui Za Zhi (2016) 0.75
Relation of Paraoxonase1, Arylesterase and Lipid Profile in Ischemic Stroke Patients. J Clin Diagn Res (2015) 0.75
Serum Basal Paraoxonase 1 Activity as an Additional Liver Function Test for the Evaluation of Patients with Chronic Hepatitis. J Clin Diagn Res (2015) 0.75
Associations between PON1 enzyme activities in human ovarian follicular fluid and serum specimens. PLoS One (2017) 0.75
Impact of antibacterial drugs on human serum paraoxonase-1 (hPON1) activity: an in vitro study. Asian Pac J Trop Biomed (2014) 0.75
Hydroxytyrosol in the Prevention of the Metabolic Syndrome and Related Disorders. Nutrients (2017) 0.75
Effect of Resveratrol and Nicotine on PON1 Gene Expression: In Vitro Study. Indian J Clin Biochem (2013) 0.75
The Paraoxonase 1 Arylesterase Activity, Total Oxidative Stress, Nitric Oxide and Vitamin C Levels in Maternal Serum, and Their Relation to Birth Weight of Newborn. J Obstet Gynaecol India (2015) 0.75
Isotope-coded protein label based quantitative proteomic analysis reveals significant up-regulation of apolipoprotein A1 and ovotransferrin in the myopic chick vitreous. Sci Rep (2017) 0.75
Coronary risk factors in people from the Indian subcontinent living in west London and their siblings in India. Lancet (1995) 5.79
Management of hyperlipidaemia: guidelines of the British Hyperlipidaemia Association. Postgrad Med J (1993) 4.28
LMNA, encoding lamin A/C, is mutated in partial lipodystrophy. Nat Genet (2000) 3.73
Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett (1991) 3.10
Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel. J Intern Med (2006) 2.55
Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis (1993) 2.48
Omega 3 fatty acids for prevention and treatment of cardiovascular disease. Cochrane Database Syst Rev (2004) 2.05
Prevention of macrovascular disease: absolute proof or absolute risk? Diabet Med (1995) 1.93
Outcome of case finding among relatives of patients with known heterozygous familial hypercholesterolaemia. BMJ (2000) 1.80
Genetic causes of familial hypercholesterolaemia in patients in the UK: relation to plasma lipid levels and coronary heart disease risk. J Med Genet (2006) 1.76
Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype? Arterioscler Thromb Vasc Biol (2001) 1.76
Estimated 10-year cardiovascular risk in a British population: results of a national screening project. Int J Clin Pract (2008) 1.75
Wrong lesson from Finnish trial of cardiovascular disease prevention. Lancet (1992) 1.74
Prevention of cardiovascular disease in systemic lupus erythematosus--proposed guidelines for risk factor management. Rheumatology (Oxford) (2003) 1.72
Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus. Atherosclerosis (1991) 1.59
Impact of migration on coronary heart disease risk factors: comparison of Gujaratis in Britain and their contemporaries in villages of origin in India. Atherosclerosis (2005) 1.55
Effects of insulin and glucose on very low density lipoprotein triglyceride secretion by cultured rat hepatocytes. J Clin Invest (1982) 1.53
Serum paraoxonase activity in patients with type 1 diabetes compared to healthy controls. Eur J Clin Invest (2002) 1.52
Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins. Curr Opin Lipidol (1996) 1.48
Influence of proteinuria on vascular disease, blood pressure, and lipoproteins in insulin dependent diabetes mellitus. Br Med J (Clin Res Ed) (1987) 1.44
Serum paraoxonase after myocardial infarction. Arterioscler Thromb Vasc Biol (1999) 1.42
Serum lipoprotein (a) in renal transplant recipients receiving cyclosporin monotherapy. Nephrol Dial Transplant (1993) 1.42
Stroke prediction and stroke prevention with atorvastatin in the Collaborative Atorvastatin Diabetes Study (CARDS). Diabet Med (2007) 1.42
Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arterioscler Thromb Vasc Biol (1995) 1.40
Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification. FEBS Lett (1998) 1.40
Severe insulin resistance, diabetes mellitus, hypertriglyceridemia, and pseudoacromegaly. J Clin Endocrinol Metab (1996) 1.39
The effects of low-dose testosterone treatment on lipid metabolism, clotting factors and ultrasonographic ovarian morphology in women. Clin Endocrinol (Oxf) (1998) 1.38
Serum paraoxonase (PON1) 55 and 192 polymorphism and paraoxonase activity and concentration in non-insulin dependent diabetes mellitus. Atherosclerosis (1998) 1.36
Lipoprotein (a): structure, properties and possible involvement in thrombogenesis and atherogenesis. Atherosclerosis (1990) 1.32
Effect of the molecular polymorphisms of human paraoxonase (PON1) on the rate of hydrolysis of paraoxon. Br J Pharmacol (1997) 1.27
Human serum paraoxonase. Gen Pharmacol (1998) 1.20
Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta-analysis of randomized controlled trials. J Intern Med (2008) 1.20
Laboratory facilities for investigating lipid disorders in the United Kingdom: results of the British Hyperlipidaemia Association survey. J Clin Pathol (1992) 1.19
Increased immunolocalization of paraoxonase, clusterin, and apolipoprotein A-I in the human artery wall with the progression of atherosclerosis. Arterioscler Thromb Vasc Biol (1997) 1.18
Established and emerging coronary risk factors in patients with heterozygous familial hypercholesterolaemia. Heart (2004) 1.17
The role of high-density lipoprotein and lipid-soluble antioxidant vitamins in inhibiting low-density lipoprotein oxidation. Biochem J (1993) 1.16
Human cholesterol metabolism and therapeutic molecules. Exp Physiol (2008) 1.15
Effect of pectin on serum lipids and lipoproteins, whole-gut transit-time, and stool weight. Lancet (1976) 1.12
Clinical value of apolipoprotein measurement. Ann Clin Biochem (1991) 1.10
How high-density lipoprotein protects against the effects of lipid peroxidation. Curr Opin Lipidol (2000) 1.08
Serum lipoprotein(a) in patients heterozygous for familial hypercholesterolemia, their relatives, and unrelated control populations. Arterioscler Thromb (1991) 1.07
Lipoprotein abnormalities in insulin-dependent diabetes mellitus. Lancet (1986) 1.04
Apolipoproteins A-I, A-II and B, lipoprotein(a) and the risk of ischaemic heart disease: the Caerphilly study. Eur J Clin Invest (2000) 1.03
The effect of atorvastatin on serum lipids, lipoproteins and NMR spectroscopy defined lipoprotein subclasses in type 2 diabetic patients with ischaemic heart disease. Atherosclerosis (2003) 1.01
Serum apolipoproteins AI and B and lipoproteins in middle aged men with and without previous myocardial infarction. Br Heart J (1986) 1.01
Alloenzymes of paraoxonase and effectiveness of high-density lipoproteins in protecting low-density lipoprotein against lipid peroxidation. Lancet (1997) 1.00
Frequency of citation and outcome of cholesterol lowering trials. BMJ (1992) 0.98
Low paraoxonase activity in type II diabetes mellitus complicated by retinopathy. Clin Sci (Lond) (2000) 0.98
Omega-3 fatty acids: their role in the prevention and treatment of atherosclerosis related risk factors and complications. Int J Clin Pract (2003) 0.98
A cross-sectional evaluation of cardiovascular risk factors in coronary heart disease associated with type 1 (insulin-dependent) diabetes mellitus. Diabetes Res Clin Pract (1992) 0.97
The immediate effect of streptokinase on serum lipoprotein(a) concentration and the effect of myocardial infarction on serum lipoprotein(a), apolipoproteins A1 and B, lipids and C-reactive protein. Atherosclerosis (1993) 0.96
Is paraoxonase related to atherosclerosis. Chem Biol Interact (1993) 0.96
Hypertriglyceridemia and hyperuricemia: effects of two fibric acid derivatives (bezafibrate and fenofibrate) in a double-blind, placebo-controlled trial. Metabolism (1988) 0.96
Polymorphisms of paraoxonase genes and low-density lipoprotein lipid peroxidation. Lancet (1999) 0.95
Protection Against Nephropathy in Diabetes with Atorvastatin (PANDA): a randomized double-blind placebo-controlled trial of high- vs. low-dose atorvastatin(1). Diabet Med (2011) 0.94
Hydrolysis of platelet-activating factor by human serum paraoxonase. Biochem J (2001) 0.94
The prevalence of hyperlipidaemia and related clinical features in insulin-dependent diabetes mellitus. Q J Med (1989) 0.94
Apolipoproteins, cardiovascular risk and statin response in type 2 diabetes: the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetologia (2008) 0.94
Familial hypercholesterolaemia commonly presents with Achilles tenosynovitis. Ann Rheum Dis (2005) 0.94
Low paraoxonase in Persian Gulf War Veterans self-reporting Gulf War Syndrome. Biochem Biophys Res Commun (2000) 0.93
Non-coronary heart disease mortality and risk of fatal cancer in patients with treated heterozygous familial hypercholesterolaemia: a prospective registry study. Atherosclerosis (2004) 0.93
Rapid emergence of effect of atorvastatin on cardiovascular outcomes in the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetologia (2005) 0.93
Paraoxonase activity in two healthy populations with differing rates of coronary heart disease. Eur J Clin Invest (2000) 0.92
Design of the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with type 2 diabetes. Diabet Med (2002) 0.90
Effects of a new fish oil concentrate on plasma lipids and lipoproteins in patients with hypertriglyceridaemia. Eur J Clin Nutr (1994) 0.90
Paraoxonase and coronary heart disease. Curr Opin Lipidol (1998) 0.90
The hunt for nutritional and pharmacological modulators of paraoxonase. Arterioscler Thromb Vasc Biol (2002) 0.90
A comparison of methods for the immunoassay of serum apolipoprotein B in man. Clin Chim Acta (1976) 0.89
Fetal and maternal lipoprotein metabolism in human pregnancy. Clin Sci (Lond) (1995) 0.89
Non-enzymatic glycation of apolipoprotein B in the sera of diabetic and non-diabetic subjects. Atherosclerosis (1992) 0.89
Hypertension, serum insulin, obesity and the metabolic syndrome. J Hum Hypertens (1998) 0.89
Relationship between serum butyrylcholinesterase activity, hypertriglyceridaemia and insulin sensitivity in diabetes mellitus. Clin Sci (Lond) (1993) 0.89
Clinical aspects of hyperlipidaemia. Br J Hosp Med (1984) 0.88
Costs of aspirin and statins in general practice. QJM (2002) 0.88
Influence of early diabetic nephropathy on very low density lipoprotein (VLDL), intermediate density lipoprotein (IDL), and low density lipoprotein (LDL) composition. Atherosclerosis (1991) 0.88
Apolipoprotein E genotyping in Alzheimer's disease. Lancet (1996) 0.88
Effect of phenobarbitone on plasma apolipoprotein B and plasma high-density-lipoprotein cholesterol in normal subjects. Clin Sci (Lond) (1979) 0.87
Comparison of the risk of fatal coronary heart disease in treated xanthomatous and non-xanthomatous heterozygous familial hypercholesterolaemia: a prospective registry study. Atherosclerosis (2003) 0.87
Double-blind placebo-controlled study of the effects of bezafibrate on blood lipids, lipoproteins, and fibrinogen in hyperlipidaemic type 1 diabetes mellitus. Diabet Med (1991) 0.86
Ethnic differences in myocardial infarction in patients with hypertension: effects of diabetes mellitus. QJM (2008) 0.86
Fetal and maternal lipoprotein metabolism in human pregnancy complicated by type I diabetes mellitus. J Clin Endocrinol Metab (1998) 0.86
The assessment of Achilles tendon size in primary hypercholesterolaemia by computed tomography. Atherosclerosis (1982) 0.86
Serum high density lipoprotein cholesterol in diabetes mellitus: an analysis of factors which influence its concentration. Clin Chim Acta (1980) 0.86
Short-term effects of beta-adrenoceptor blocking drugs with and without cardioselectivity and intrinsic sympathomimetic activity on lipoprotein metabolism in hypertriglyceridaemic patients and in normal men. Clin Sci (Lond) (1985) 0.85
Lipoprotein (a) and microvascular disease in type 1 (insulin-dependent) diabetes. Diabet Med (1991) 0.85
Triglycerides and small dense low density lipoprotein in the discrimination of coronary heart disease risk in South Asian populations. Atherosclerosis (2009) 0.85
Baseline characteristics in the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with Type 2 diabetes. Diabet Med (2004) 0.84
Abnormalities of VLDL, IDL, and LDL characterize insulin-dependent diabetes mellitus. Arterioscler Thromb (1992) 0.84
Preventing cardiovascular disease in hypertension: effects of lowering blood pressure and cholesterol. QJM (2002) 0.84
Placebo-controlled trial of the effects of guar gum and metformin on fasting blood glucose and serum lipids in obese, type 2 diabetic patients. Diabet Med (1990) 0.83
Influence of immunosuppressive therapy on lipoprotein(a) and other lipoproteins following renal transplantation. Nephron (1997) 0.83
All-cause and cardiovascular mortality in treated patients with severe hypertriglyceridaemia: A long-term prospective registry study. Atherosclerosis (2010) 0.83
Serum esterase activities and hyperlipidaemia in the streptozotocin-diabetic rat. Biochim Biophys Acta (1990) 0.82
Paraoxonase: another factor in NIDDM cardiovascular disease. Lancet (1995) 0.82
Elevation of skeletal muscle isoform of serum creatine kinase in heterozygous familial hypercholesterolaemia. J Intern Med (1990) 0.82
Serum and urinary high density lipoproteins in glomerular disease with proteinuria. Kidney Int (1986) 0.81
Lack of protection against oxidative modification of LDL by avian HDL. Biochem Biophys Res Commun (1998) 0.81
Serum and lipoprotein apolipoprotein B levels in normal subjects and patients with hyperlipoproteinaemia. Clin Chim Acta (1978) 0.81
Cost-effectiveness of primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes: results from the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetologia (2007) 0.81